The 29 epigenetic chemical compounds, which are drug candidates currently in preclinical or clinical development, were key epigenetic regulatory proteins by Structural Genomics Consortium (SGC) collection and classical epigenetic targets.[15] As is shown in Figure 2A, DNMTs inhibitor, KDMs inhibitor, DOT1L inhibitor and HDACs inhibitor showed consistently low IC50s across all three melanoma cell lines among 29 epigenetic chemical compounds. The gene discussed is DOT1L; the disease is melanoma.